Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 22, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
May 30, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
May 01, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 22, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
February 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
February 21, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
January 09, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
January 05, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
January 04, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
December 04, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
November 16, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 08, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 26, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
October 23, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 19, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
October 16, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CPRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright